Agenus Inc. (NASDAQ:AGEN) Short Interest Down 6.4% in November

Agenus Inc. (NASDAQ:AGEN) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,620,000 shares, a decrease of 6.4% from the October 31st total of 2,800,000 shares. Approximately 11.8% of the company’s shares are short sold. Based on an average trading volume of 452,300 shares, the days-to-cover ratio is presently 5.8 days.

Analyst Ratings Changes

A number of analysts have commented on AGEN shares. HC Wainwright reaffirmed a “neutral” rating and set a $7.00 price target on shares of Agenus in a research report on Friday. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Finally, B. Riley reduced their price objective on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Barclays PLC boosted its holdings in Agenus by 295.3% in the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 20,777 shares during the period. Geode Capital Management LLC raised its position in Agenus by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after purchasing an additional 32,016 shares during the period. EP Wealth Advisors LLC purchased a new position in Agenus in the 3rd quarter worth $55,000. State Street Corp raised its position in Agenus by 2.1% in the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares during the period. Finally, Point72 DIFC Ltd increased its position in shares of Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 11,542 shares during the period. 61.46% of the stock is owned by institutional investors.

Agenus Price Performance

Shares of NASDAQ:AGEN opened at $3.73 on Tuesday. The firm has a fifty day moving average price of $4.15 and a two-hundred day moving average price of $8.04. Agenus has a one year low of $2.50 and a one year high of $19.69. The company has a market cap of $87.51 million, a price-to-earnings ratio of -0.33 and a beta of 1.39.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.